Article
Author(s):
Rotterdam, Netherlands-Four years is a reasonable interval for prostatecancer screening, concluded investigators from the European Randomized Studyof Screening for Prostate Cancer (ERSPC).
Upper tract urothelial carcinoma: Key considerations and patient cases
Introducing Pearls & Perspectives, with Amy Pearlman, MD!
Biomarkers in urology: Policy and legislative advances
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
AUA 2025: What to watch for in urologic oncology
U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers
10 urology trials in progress to be highlighted at AUA 2025
Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan